169 related articles for article (PubMed ID: 17308987)
1. Use of beta-blockers and the risk of hip/femur fracture in the United Kingdom and The Netherlands.
de Vries F; Souverein PC; Cooper C; Leufkens HG; van Staa TP
Calcif Tissue Int; 2007 Feb; 80(2):69-75. PubMed ID: 17308987
[TBL] [Abstract][Full Text] [Related]
2. Use of alpha-blockers and the risk of hip/femur fractures.
Souverein PC; Van Staa TP; Egberts AC; De la Rosette JJ; Cooper C; Leufkens HG
J Intern Med; 2003 Dec; 254(6):548-54. PubMed ID: 14641795
[TBL] [Abstract][Full Text] [Related]
3. Risk of hip/femur fracture after stroke: a population-based case-control study.
Pouwels S; Lalmohamed A; Leufkens B; de Boer A; Cooper C; van Staa T; de Vries F
Stroke; 2009 Oct; 40(10):3281-5. PubMed ID: 19661475
[TBL] [Abstract][Full Text] [Related]
4. Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study.
Pouwels S; Lalmohamed A; Souverein P; Cooper C; Veldt BJ; Leufkens HG; de Boer A; van Staa T; de Vries F
Osteoporos Int; 2011 Mar; 22(3):903-10. PubMed ID: 20585937
[TBL] [Abstract][Full Text] [Related]
5. Dopaminergic drugs and the risk of hip or femur fracture: a population-based case-control study.
Arbouw ME; Movig KL; van Staa TP; Egberts AC; Souverein PC; de Vries F
Osteoporos Int; 2011 Jul; 22(7):2197-204. PubMed ID: 20967420
[TBL] [Abstract][Full Text] [Related]
6. Use of beta-blockers and risk of fractures.
Schlienger RG; Kraenzlin ME; Jick SS; Meier CR
JAMA; 2004 Sep; 292(11):1326-32. PubMed ID: 15367554
[TBL] [Abstract][Full Text] [Related]
7. Use of anti-depressants and the risk of fracture of the hip or femur.
van den Brand MW; Pouwels S; Samson MM; van Staa TP; Thio B; Cooper C; Leufkens HG; Egberts AC; Verhaar HJ; de Vries F
Osteoporos Int; 2009 Oct; 20(10):1705-13. PubMed ID: 19238308
[TBL] [Abstract][Full Text] [Related]
8. Use of beta-2 agonists and risk of hip/femur fracture: a population-based case-control study.
de Vries F; Pouwels S; Bracke M; Leufkens HG; Cooper C; Lammers JW; van Staa TP
Pharmacoepidemiol Drug Saf; 2007 Jun; 16(6):612-9. PubMed ID: 16998945
[TBL] [Abstract][Full Text] [Related]
9. Does Angiotensin-Converting Enzyme Inhibitor and β-Blocker Use Reduce the Risk of Primary Liver Cancer? A Case-Control Study Using the U.K. Clinical Practice Research Datalink.
Hagberg KW; Sahasrabuddhe VV; McGlynn KA; Jick SS
Pharmacotherapy; 2016 Feb; 36(2):187-95. PubMed ID: 26846893
[TBL] [Abstract][Full Text] [Related]
10. Risk of hip/femur fractures in patients using antipsychotics.
Hugenholtz GW; Heerdink ER; van Staa TP; Nolen WA; Egberts AC
Bone; 2005 Dec; 37(6):864-70. PubMed ID: 16111927
[TBL] [Abstract][Full Text] [Related]
11. Comparative study of modified release alpha-blocker exposure in elderly patients with fractures.
Hall GC; McMahon AD
Pharmacoepidemiol Drug Saf; 2007 Aug; 16(8):901-7. PubMed ID: 17443863
[TBL] [Abstract][Full Text] [Related]
12. The risk of bone fracture after long-term risperidone exposure is not increased compared to other atypical antipsychotics: A retrospective cohort study.
Shen SP; Liu Y; Qiu H; Tsai KY; Wu HC; Liang WM; Shu M; Chou FH
PLoS One; 2019; 14(9):e0221948. PubMed ID: 31487309
[TBL] [Abstract][Full Text] [Related]
13. Association between beta-blockers, other antihypertensive drugs and psoriasis: population-based case-control study.
Brauchli YB; Jick SS; Curtin F; Meier CR
Br J Dermatol; 2008 Jun; 158(6):1299-307. PubMed ID: 18410416
[TBL] [Abstract][Full Text] [Related]
14. Levothyroxine treatment and occurrence of fracture of the hip.
Sheppard MC; Holder R; Franklyn JA
Arch Intern Med; 2002 Feb; 162(3):338-43. PubMed ID: 11822927
[TBL] [Abstract][Full Text] [Related]
15. Use of inhaled and oral glucocorticoids, severity of inflammatory disease and risk of hip/femur fracture: a population-based case-control study.
de Vries F; Pouwels S; Lammers JW; Leufkens HG; Bracke M; Cooper C; van Staa TP
J Intern Med; 2007 Feb; 261(2):170-7. PubMed ID: 17241182
[TBL] [Abstract][Full Text] [Related]
16. Antipsychotic use and the risk of hip/femur fracture: a population-based case-control study.
Pouwels S; van Staa TP; Egberts AC; Leufkens HG; Cooper C; de Vries F
Osteoporos Int; 2009 Sep; 20(9):1499-506. PubMed ID: 19156348
[TBL] [Abstract][Full Text] [Related]
17. Use of organic nitrates and the risk of hip fracture: a population-based case-control study.
Pouwels S; Lalmohamed A; van Staa T; Cooper C; Souverein P; Leufkens HG; Rejnmark L; de Boer A; Vestergaard P; de Vries F
J Clin Endocrinol Metab; 2010 Apr; 95(4):1924-31. PubMed ID: 20130070
[TBL] [Abstract][Full Text] [Related]
18. β-Adrenergic receptor antagonists and fracture risk: a meta-analysis of selectivity, gender, and site-specific effects.
Toulis KA; Hemming K; Stergianos S; Nirantharakumar K; Bilezikian JP
Osteoporos Int; 2014 Jan; 25(1):121-9. PubMed ID: 24114396
[TBL] [Abstract][Full Text] [Related]
19. Beta-adrenergic blockers reduce the risk of fracture partly by increasing bone mineral density: Geelong Osteoporosis Study.
Pasco JA; Henry MJ; Sanders KM; Kotowicz MA; Seeman E; Nicholson GC;
J Bone Miner Res; 2004 Jan; 19(1):19-24. PubMed ID: 14753732
[TBL] [Abstract][Full Text] [Related]
20. The risk of fracture in incident multiple sclerosis patients: the Danish National Health Registers.
Bazelier MT; Bentzen J; Vestergaard P; Stenager E; Leufkens HG; van Staa TP; de Vries F
Mult Scler; 2012 Nov; 18(11):1609-16. PubMed ID: 22472998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
